Simplifying Global Compliance
FDAnews Drug Daily Bulletin
AstraZeneca Adds Lung-Drug Offerings With Almirall Deal
July 31, 2014
AstraZeneca, the U.K. drugmaker that resisted a Pfizer Inc. takeover attempt, is building up its respiratory business by buying the rights to Almirall lung medicines for $875 million.
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing